findmyKOL
Clinical trialNCT02560298UnknownPhase 2Interventional

Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer

SponsorECOG-ACRIN Cancer Research GroupEnrollment91Anal Basaloid CarcinomaAnal Canal Cloacogenic CarcinomaAnal Squamous Cell CarcinomaMetastatic Anal Canal CarcinomaRecurrent Anal Canal CarcinomaStage IIIB Anal Canal Cancer+1 more conditions
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Ecog-Acrin Cancer Research Group

    Philadelphia, Pennsylvania, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
23 Aug 2016
Primary completion
31 Aug 2021
Completion
31 Aug 2023
Last update posted
22 Jun 2023
Registered enrollment
91
Registry id
NCT02560298

Cross-registrations

EU-CTR / CTIS (EudraCT)2013-001949-13

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.